

## Supplementary References

- S1. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenti P. Sodium intake, ACE inhibition, and progression to ESRD. *J Am Soc Nephrol.* 2012; 23 (1):165-173.
- S2. Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers *Kidney Int.* 2012; 82 (3): 330-337.
- S3. Stevens PE, Levin A. Kidney Disease: Improving global outcomes chronic kidney disease guideline development work group members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med.* 2013 Jun 4;158(11):825-30. doi: 10.7326/0003-4819-158-11-201306040-00007. PMID: 23732715.
- S4. Lokelma® (sodium zirconium cyclosilicate) for oral suspension: US prescribing information [Internet]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; Available from: <https://www.azpicentral.com/lokelma/lokelma.pdf> [cited 2020 November 16].
- S5. Colbert GB, Patel D, Lerma EV. Patiromer for the treatment of hyperkalemia. *Expert Rev Clin Pharmacol.* 2020 Jun;13(6):563-570. doi: 10.1080/17512433.2020.1774363. Epub 2020 Jun 8.
- S6. Cooper K., Letter to the editor regarding 'Patiromer for the treatment of hyperkalemia' *Expert Rev Clin Pharmacol.* 2020 Oct 12;1-2. doi: 10.1080/17512433.2020.1828542. Online ahead of print.
- S7. Lund-Johansen P, Strandén E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. *Journal of Hypertension:* May 2003 - Volume 21 - Issue 5 - p 1003-1010.

---